Breast Cancer Coverage from Every Angle

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Trial Results of IMMU-132

Posted: Thursday, December 7, 2017

Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses the efficacy of sacituzumab govitecan (IMMU-132), an anti–Trop-2-SN-38 antibody-drug conjugate, as ≥ 3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.